NIH Awards BellBrook Labs Phase II Grant to Develop Drugs Targeting the cGAS-STING Pathway for Lupus and Related Autoimmune Diseases

cGAS Phase II Press Release Graphic
The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule antagonists of cyclic GAMP synthase (cGAS). The grant will enable BellBrook to optimize their cGAS lead molecules and test their efficacy for treating lupus-related UV light sensitivity
Read more
No Comments

New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay

New cGAS TR-FRET Assay
Launched in November 2019, the Transcreener cGAMP cGAS Assay has generated a great deal of interest in the drug discovery community. While fluorescence polarization (FP) readouts offer a stable and robust option, some researchers prefer time-resolved Förster-resonance-energy-transfer (TR-FRET) readouts for large screens. After months of development, BellBrook Labs is pleased to announce the addition of
Read more
No Comments

Previously Recorded Webinar – Streamline cGAS Inhibitor Discovery with the Transcreener® cGAS Assay

Webinar Graphic
The immune system uses the recognition of foreign nucleic acids and subsequent type I interferon production as a first line of defense in response to microbial invaders. Recent research has validated one key to this cascade, a unique cyclic dinucleotide – cGAMP. The enzyme cGAS produces this recently discovered molecular messenger. As an apoenzyme, cGAS
Read more
No Comments

BellBrook Labs Launches Transcreener cGAS Activity Assay to Accelerate Drug Discovery

New Transcreener cGAS Assay
The new Transcreener cGAMP cGAS Assay directly measures the product cGAMP, in a cGAS enzymatic reaction allowing researchers to screen vast compound libraries for novel modulators. The assay will be used to discover and develop new treatments for autoimmune diseases and cancer by targeting the cGAS-STING pathway. Madison, WI – Researchers at BellBrook Labs have
Read more
No Comments

BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases

cGAS Inhibitors Grant
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway. Madison, WI – July 2019
Read more
No Comments

NIH Awards BellBrook Labs Phase II Grant to Develop HTS Assays Targeting the cGAS-STING Pathway for Autoimmune Diseases and Cancer

Autoimmune Disease News
The National Institutes of General Medical Sciences (NIGMS) recently awarded BellBrook Labs a $1 million phase II Small Business Innovative Research (SBIR) grant to develop new assays to detect cyclic GMP-AMP (cGAMP) levels in biological samples. The assays will be used to discover, develop, and monitor new treatments for autoimmune diseases and cancer by targeting
Read more
No Comments

New Posters from DOT 2017

Poster Presentations A Homogenous, High Throughput Assay to Measure Guanine Nucleotide Exchange Factor Activity Using Transcreener® GDP Assay Guanine nucleotide exchange factors (GEFs) positively regulate Rho GTPases by accelerating GDP dissociation to allow formation of the active, GTP-bound complex. Development of inhibitors that specifically disrupt GEF action on a target Rho GTPase may be a
Read more
No Comments

BellBrook Labs Awarded NIH Grant to Develop a High Throughput cGAS Assay for Cancer and Autoimmune Disease Drug Discovery

BellBrook Labs was recently awarded a $288,000 SBIR Phase I grant from the National Institutes of General Medical Sciences (NIGMS) to develop an HTS assay for cyclic GAMP synthase, an enzyme that triggers immune responses to viruses and tumors. The new assay will be used in an effort to screen for cGAS enzyme modulators as
Read more
No Comments

Fighting Infection’s Ghost

Aicardi–Goutières syndrome (AGS) is a rare and brutal genetic condition. Most infants born with the syndrome are asymptomatic at birth, but about 1 in 5 have enlarged spleen and liver, elevated liver enzymes in the blood, decreased platelet level, and abnormal neurological responses. Over the first year of life, things get much worse: episodes of
Read more
No Comments

Viruses take the STING out of innate immunity

Viral trespassers leave traces of themselves as they overtake cells. The presence of hallmark viral molecules—called PAMPs, for pathogen-associated molecular patterns—allows innate immune system sensors to detect the trail of viral substances as effectively as Sherlock Holmes in miniature. Some of these sensors, or pattern recognition receptors (PRRs), nose out viral DNA and RNA. When
Read more
No Comments